The purpose of the study is to see whether the active drug can lower the risk of brain ischemia and related clot‑related problems after the bleed. Over a period of 14 days, participants are monitored for signs of blood clots that could block vessels (thromboembolic events) and for any neurological worsening. Doctors use a brain scan called MRI and a scoring system known as NIHSS to check for new areas of damage, and they also watch for a condition called delayed cerebral ischemia, which is a later reduction in blood flow that can happen after the initial bleed. After the treatment period, follow‑up visits and scans are done to assess recovery.

Participants will take the study tablets once daily for about 12 weeks and will attend regular clinic visits where they will complete questionnaires and undergo simple tests. One questionnaire, the Epworth Sleepiness Scale, asks about the likelihood of falling asleep in everyday situations to measure daytime sleepiness. Another test, the Maintenance of Wakefulness Test, measures how long a person can stay awake while trying to stay alert. Throughout the study, researchers will monitor how the medication affects sleepiness and overall well‑being, while also checking for any side effects.

The purpose of the trial is to evaluate the safety and effectiveness of this drug combination. The study begins with a short safety‑checking phase and, if tolerated, moves to a larger phase that looks at how well the treatment shrinks or controls the tumor. Participants receive the infusions every few weeks and undergo regular imaging scans to see changes in tumor size; the study continues until the disease progresses, the participant chooses to stop, or the study ends.

In the trial, participants are randomly assigned to either keep taking the medication right up to the morning of the surgery or to stop it three days before the procedure. The operation is performed using cardiopulmonary bypass, a technique that temporarily takes over the work of the heart and lungs. After surgery, patients are monitored for about a month to see whether they develop problems such as damage to the heart muscle measured by an increase in high-sensitivity troponin I, a blood test that shows heart injury, or experience low cardiac output syndrome, which means the heart is not pumping enough blood. Other complications that are checked include a rare condition called euglycaemic ketoacidosis (a buildup of acids despite normal blood sugar), acute renal failure (sudden kidney problems) assessed using the KDIGO scoring system, need for additional hospital stays for heart failure, and overall survival. The follow‑up period lasts 30 days after the surgery, during which length of hospital stay and quality of life are also recorded.

The purpose of the study is to determine whether the drug improves pain levels after 12 weeks compared with placebo. Participants receive an infusion at the start of the study, then again at about 12 weeks and 24 weeks, with follow‑up visits extending to 36 weeks. At each visit, pain is recorded using simple age‑appropriate scales that involve faces or a line marked from “no pain” to “worst pain.” Whole‑body imaging with MRI (a scan that creates detailed pictures of the bones) is performed to see how many bone lesions are present. Safety checks include monitoring for flu‑like symptoms, headache, and low levels of phosphate or calcium in the blood.

The purpose of the study is to evaluate a new way of monitoring patients using a method called ctDNA-based surveillance. This involves checking for tiny pieces of cancer DNA in the blood, which can indicate if the cancer is coming back. The study will compare this new method with standard monitoring techniques to see if it can help detect relapses earlier and improve survival rates. Participants will undergo regular scans and blood tests over a period of time to monitor their condition.

Throughout the study, researchers will collect information on how well the new monitoring method works, including any side effects from the 68Ga-FAPI-46 PET-CT scans. The study will also look at how the new method compares to existing imaging procedures, such as 18F-FDG PET-CT, in terms of detecting cancer spread. The trial is expected to run until 2028, with the goal of improving early detection and treatment strategies for patients with high-risk triple-negative breast cancer.

The purpose of the study is to learn about the safety of BIIB080 and whether it can improve symptoms in participants. Participants will receive the treatment through an injection into the spinal fluid, a method known as intrathecal use. The study will last for a period of 76 weeks, during which participants will be monitored for changes in their cognitive abilities and overall health. The study aims to understand how different doses of the treatment affect the symptoms of Alzheimer’s disease.

Throughout the study, participants will undergo various assessments to track their progress. These assessments include tests to measure memory and thinking skills, as well as monitoring for any side effects or adverse events. The study is designed to provide valuable information on the potential benefits and safety of BIIB080 for individuals with early stages of Alzheimer’s disease.

The purpose of this study is to assess the safety of using Durvalumab in combination with chemotherapy for patients who have not received prior treatment for their advanced biliary tract cancer. Participants in the study will receive these treatments over a period of time, and their health will be monitored closely to observe any effects of the treatment. The study will also include a group of participants who will receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.

Throughout the study, participants will undergo regular health check-ups and assessments to monitor their response to the treatment. The study aims to provide valuable information on how well the combination of Durvalumab and chemotherapy works in treating advanced biliary tract cancers and to ensure the safety of the treatment for patients. The study is expected to continue until March 2025, with recruitment having started in September 2023.

The main aim of the trial is to assess whether the drug improves daytime alertness in participants with this condition. Volunteers will be randomly assigned to receive either the active medication or the inactive comparator, and they will take the assigned tablet each day for approximately twelve weeks. Throughout the study period, participants will attend regular visits where simple questionnaires and brief safety checks will be performed to monitor how they feel and to ensure the treatment is well tolerated.

The purpose of the study is to assess the effectiveness and safety of OATD-01 over a 12-week period. Participants will be randomly assigned to receive either OATD-01 or a placebo, and neither the participants nor the researchers will know which treatment is being administered. Throughout the study, participants will undergo various assessments, including imaging tests like [18F]FDG PET/CT, to monitor changes in lung inflammation and overall health. The study aims to determine if OATD-01 can reduce the inflammation in the lungs and improve lung function and quality of life for those with active pulmonary sarcoidosis.

Participants will be closely monitored for any side effects or changes in their health during the study. The trial will also collect data on various health parameters, such as lung function tests and quality of life questionnaires, to evaluate the overall impact of the treatment. The study is expected to provide valuable insights into the potential benefits of OATD-01 for individuals with active pulmonary sarcoidosis.

After the first treatment with apalutamide and hormone therapy, the study compares continued treatment with apalutamide plus docetaxel and hormone therapy. Treatment is given over time, with regular study visits and follow-up checks. During the study, doctors watch for changes in the cancer, possible side effects, and how long the treatment continues to work. The study is Phase III, which means it is a late-stage trial designed to better understand how well this treatment approach works and how safe it is.

In this study, participants are assigned to one of the treatment groups by chance. One group receives tirabrutinib alone, and the other group receives rituximab plus temozolomide. Treatment is given over a period of time with regular study visits, and health is checked throughout the study to see how the disease responds and how long the disease stays under control. The study also looks at overall survival, which means how long people live after joining the study, and at changes in steroid medicine use.

This is a Phase 3 study, which means the treatment is being compared in a larger group of people to help show how well it works and how safe it is. It is a randomized study, so the treatment group is chosen by chance, and it is open-label, which means both the study team and the participants know which treatment is being given.

The purpose of the study is to determine if niraparib can help patients live longer without the disease getting worse, compared to temozolomide. Participants in the study will be randomly assigned to receive either niraparib or temozolomide. The study will monitor the participants over time to see how the treatments affect their health and the progression of their glioblastoma.

Throughout the study, researchers will also look at how the treatments impact overall survival, which means the length of time patients live after starting the treatment. Additionally, the study will assess the participants’ symptoms, quality of life, and any side effects they may experience. This information will help determine the safety and effectiveness of niraparib compared to temozolomide for treating this specific type of glioblastoma.

In the study, treatment is given before surgery, and then the planned surgery is performed if possible. During the study, there are regular checkups, blood tests, and other routine medical exams to watch for side effects and to see how the disease is responding. After surgery, follow-up continues for a period of time to look for any return of the cancer and to monitor overall health.

Durvalumab is a type of medicine that helps the immune system attack cancer cells. The chemotherapy used with it is ddMVAC, a group of cancer medicines that are commonly given together for bladder cancer. The study is open-label, which means both the medical team and the participant know which treatment is being given.

People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

The main purpose of this research is to determine if the combination of these three medications can help patients live longer compared to using docetaxel by itself. The study involves two groups of patients – one receiving all three medications, while the other group receives only docetaxel. The medications are given through different methods: tislelizumab and docetaxel are given through an intravenous infusion (into a vein), while N-803 is given as a subcutaneous injection (under the skin).

During the study, patients will receive treatment and have regular check-ups to monitor their health and how well the treatment is working. The treatment will continue as long as it appears to be helping and the side effects are manageable. Doctors will use special scanning techniques to measure if the tumors are shrinking and will track how long patients live after starting the treatment.

Participants are randomly placed into two groups: one receives the iron infusion soon after the first visit, while the other group waits for a short period before receiving the same infusion. All participants complete a questionnaire about their leg symptoms, sleep quality, mood, and daily functioning at the start of the study and again after about three months. Simple blood tests are done to check iron levels, and a brief overnight sleep recording may be performed to assess sleep patterns. The study follows each person for several months to see how the symptoms change after the treatment.

The purpose of the study is to see whether a precision‑medicine strategy that combines these targeted drugs can improve the rate of blood‑cell recovery, known as hematologic remission, compared with standard approaches. Hematologic remission means that the abnormal blood cells are reduced to very low levels, indicating that the leukemia is under control.

Participants are randomly assigned to receive either the personalized drug combination or the standard treatment. After starting therapy, they will have regular clinic visits and simple blood tests over several months to monitor response and any side effects. The study continues for a period that allows researchers to observe how long the response lasts and whether the disease returns.

The purpose of the trial is to evaluate the safety and efficacy of the new combination therapy. Over a period of about four weeks, subjects will take the study medication once daily, while other participants receive a matching placebo. Safety will be monitored through reports of any side effects, regular blood tests, standard 12‑lead ECG recordings to check heart rhythm, and measurements of Sweat chloride levels, which reflect how the disease is affecting the body.

Effectiveness will be assessed by measuring lung function using the percent predicted forced expiratory volume in one second (ppFEV1) and by having participants complete a disease‑specific questionnaire that evaluates breathing symptoms (CFQ R). The study involves several clinic visits for these tests and for overall health checks.

The main aim of the study is to find out whether the medicine is safe and can help shrink or control the cancer. Participants will be placed into different groups that receive the drug in one of the ways described, and they will have regular visits where doctors check for side effects, take blood samples, and perform imaging scans to see how the disease is responding. The study will follow each person for several months to monitor health and any changes in the cancer.

People in the study are assigned by chance to receive either orelabrutinib or placebo. The study is set up so that neither the participants nor the study doctors know which treatment is being given during the trial. Treatment is taken over time, and the study follows participants to see how their condition changes during the study period.

PPMS can affect walking, balance, hand use, and other body functions. Disability progression means a gradual increase in these problems. The study is designed to compare how often this worsening happens in the two groups.

The study is open label, which means the treatment is known and no hidden treatment is used. It is designed for people who finished a previous remibrutinib study and were thought to be doing well enough to continue treatment. During the trial, remibrutinib is taken over a longer period of time, and health is watched for any side effects, including common adverse events and more serious serious adverse events.

After the earlier treatment has finished, participants are assigned to receive either pumitamig or durvalumab. The study is randomized, which means the treatment is chosen by chance, and open-label, which means the treatment is known. The study team then follows the cancer over time and watches for changes, such as whether it stays stable, shrinks, or grows, and also checks how safe each medicine is and how well it is tolerated.

The main aim of the study is to evaluate the long‑term safety and tolerability of the medication. After a previous trial, participants may continue receiving the study drug or placebo for an extended period, with regular clinic visits where health status is checked, blood samples are taken, and any side effects are recorded.

During the study, doctors will look for improvements in joint symptoms and overall disease activity using standard assessment tools, and they will monitor laboratory results and vital signs to ensure the medication remains safe over time.

The purpose of the study is to evaluate the one‑year effectiveness of guselkumab in real‑world patients with Crohn’s disease. Participants receive regular injections of the medication for up to twelve months and attend clinic visits at about 12, 24 and 48 weeks. During these visits doctors check how the patient feels, review stool tests that measure a protein called fecal calprotectin (a sign of gut inflammation), and look at the intestines using one of three imaging methods: an endoscopy (a thin camera inserted to see inside the gut), an MRI (a scan that uses magnets to create pictures of the body), or IUS (an ultrasound performed on the skin). Questions about quality of life are also completed to see if the treatment helps patients feel better overall.

The purpose of the study is to test whether BMS-986504 combined with nab-paclitaxel and gemcitabine can help people live longer and delay the time until the cancer gets worse compared to placebo combined with nab-paclitaxel and gemcitabine. The study will also look at whether the combination treatment can shrink tumors and control tumor growth. People joining the study must have their cancer confirmed through tissue samples and must have evidence of the MTAP deletion in their tumor. The cancer must have spread to other parts of the body with at least one area that can be measured on scans.

During the study, people will be randomly assigned to receive either BMS-986504 or placebo, both given together with nab-paclitaxel and gemcitabine. The study will track how long it takes for the cancer to worsen on scans and how long people survive. Researchers will also measure how much tumors shrink, how long any shrinkage lasts, and how many people experience tumor control or shrinkage. People in the study must not have received any cancer treatment for their spread disease before joining, although they may have received up to one cycle of nab-paclitaxel and gemcitabine before being assigned to a treatment group.

The study compares three different treatment approaches: standard treatment with prednisolone for 30 days, extended prednisolone treatment for 60 days, or a combination of standard prednisolone treatment with N-acetylcysteine given over 5 days. The purpose is to determine which treatment method is most effective in helping patients recover from severe alcoholic hepatitis and maintain stable liver function after 90 days.

During the study, participants will receive either prednisolone tablets taken by mouth, N-acetylcysteine given through an intravenous line (directly into a vein), or placebo, depending on their assigned treatment group. Some patients will receive additional supportive treatments including dextrose and saline solutions. The study will monitor patients’ liver function and overall health throughout the treatment period and follow-up visits.

The treatment involves receiving bevacizumab through an intravenous infusion (a drip into the vein) and taking trifluridine as oral tablets. Participants will be randomly assigned to receive either the standard treatment schedule or the new two-weekly schedule. The treatment period may last up to 24 months, during which patients will have regular check-ups to monitor their health and any side effects.

The study will track how often patients experience severe neutropenia with both treatment schedules. Other aspects being monitored include how long patients survive, whether their cancer responds to treatment, and how well patients tolerate the medications. This information will help determine if the new treatment schedule is safer and more effective than the current standard approach.

The medications being tested contain active substances called trospium chloride and xanomeline tartrate. They come in the form of capsules that are taken by mouth. The study will involve patients who have previously participated in related research studies of these medications.

During the study, researchers will monitor various aspects of participants’ health, including any side effects, changes in body weight, blood pressure, heart rate, and mental function. They will also check for any unusual movements, restlessness, and other health-related factors to ensure the medications’ safety over extended use.

Participants in the study will receive the treatment through an infusion, which means the medication will be given directly into a vein. The study will follow a single-arm, open-label design, meaning all participants will receive the same treatment, and both the participants and the researchers will know what treatment is being given. The study will take place over several months, with regular check-ups to monitor the participants’ health and the effects of the treatment. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the actual treatment.

The study aims to gather information on how well the treatment works and any side effects that may occur. This information will help doctors understand the potential benefits and risks of using Durvalumab in combination with chemotherapy for treating advanced biliary tract cancers. Participants will be closely monitored throughout the study to ensure their safety and well-being. The study is expected to continue until 2026, with recruitment starting in 2024.

The purpose of the study is to compare the effectiveness of a new medicine with that of standard chemotherapy. The investigational drug being tested is Sofetabart Mipitecan (LY4170156). For participants with platinum-resistant disease, the new drug may be given alone and compared with the doctor’s choice of chemotherapy drugs such as carboplatin, paclitaxel, gemcitabine, topotecan or doxorubicin, or with Mirvetuximab Soravtansine. For those with platinum-sensitive disease, the new drug is combined with bevacizumab and compared with a standard platinum‑based two‑drug chemotherapy regimen plus bevacizumab.

Participants receive the study medicines through an IV infusion every few weeks and attend regular clinic visits where doctors perform physical examinations and imaging scans to check how the cancer is responding. Treatment continues until the cancer grows, side effects become unacceptable, or the study period ends, which may be several months for each participant.

The main goal is to assess the long‑term safety and tolerability of the medicine, meaning researchers will watch for any side effects or problems over an extended period. After the initial treatment period, participants will continue to attend regular visits where doctors will ask about health changes, perform a simple nasal examination, and may take a small blood sample to check drug levels. The study also records whether participants need additional treatments such as a short course of a systemic corticosteroid (a pill that reduces inflammation throughout the body) or sinus surgery.

The purpose of the study is to demonstrate the efficacy of maintaining RTX as a maintenance strategy in individuals with stabilized SSc‑ILD following RTX induction treatment. Participants receive the assigned infusion every few months for a total period of about 18 months, with clinic visits scheduled at regular intervals to monitor health.

During the study, lung function is checked using measurements such as FVC, which assesses the amount of air a person can forcefully exhale, and DLCO, which evaluates how well oxygen passes from the lungs into the blood. Imaging of the chest is performed with a HRCT scan, and physical capacity is measured with a 6‑min walk test that records the distance walked in six minutes. Additional assessments include questionnaires about quality of life and safety checks.

The purpose of this study is to determine if the combination of ceralasertib and durvalumab is more effective than docetaxel in treating patients with this type of lung cancer. Participants in the study will be randomly assigned to receive either the combination therapy or docetaxel. The study will monitor the overall survival of participants, which refers to the length of time patients live after starting the treatment. Other aspects being evaluated include how long the cancer stays under control, the quality of life reported by participants, and the safety and tolerability of the treatments.

The study will take place over a period of time, with participants receiving treatment for up to 24 months. During this time, participants will have regular check-ups and assessments to monitor their health and the progress of their cancer. The study aims to provide valuable information on the effectiveness and safety of these treatments for patients with advanced or metastatic non-small cell lung cancer.